Acumen Pharmaceuticals, Inc. (ABOS) announced a $35.75 million private placement of its common stock at a price of $3.30 per share to support the development of its next generation of Alzheimer's disease candidates. The financing is expected to close on or about March 16, 2026, subject to customary conditions.
The company said the proceeds will primarily fund its Enhanced Brain Delivery (EBD) program, which aims to improve how Alzheimer's drugs reach the brain.
Acumen is developing antibodies that target toxic amyloid beta oligomers-believed to be early drivers of Alzheimer's disease- and the new funding will help advance potential best-in-class molecules toward clinical testing. The company expects to select a first clinical candidate from its next-generation EBD program and file an IND by mid-2027.
Acumen's pipeline includes Sabirnetug (ACU193), its current lead antibody, along with a subcutaneous formulation of Sabirnetug and its EBD program being developed in partnership with JCR Pharmaceuticals. Sabirnetug is currently being evaluated in ALTITUDE-AD, a Phase 2 trial in early Alzheimer's disease, with topline results from this study in late 2026.
The company plans to use early 2026 non-clinical data to determine whether to advance up to two EBD development candidates under its collaboration agreement.
Acumen ended the third quarter of 2025 with $136.1 million in cash, cash equivalents and marketable securities, which it expects will fund operations into early 2027.
ABOS has traded between $2.98 and $3.34 over the past year. The stock closed Friday's trading session (March 13, 2026) at $3.27, down 0.91%. In pre-market trading the stock is up $3.90, up 20%, touching a new 52-week high.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.